BACKGROUND
Anti-amyloid antibodies slow cognitive and functional decline in individuals with early symptomatic Alzheimer's disease, but few studies have examined changes associated with these treatments in plasma biomarkers linked to neurodegeneration. We analysed changes in a panel of 130 plasma proteins and their ass...
Rui Mu, Anna Hofmann, Katherine Gong et al.· Lancet Neurology· 1 citation
Background and Objectives Stroke and dementia are leading causes of death and disability worldwide, requiring enhanced preventive strategies. Glucagon-like peptide-1 receptor agonists (GLP-1RA), widely used for type 2 diabetes (T2D) and obesity, have demonstrated pleiotropic effects, including cardiovascular benefits,...
Ilana Caro-Châtelier, M. Sargurupremraj, Cheng-Ran Yang et al.· Neurology: Genetics· 1 citation
The Vertebrate Regulatory MOdule Detector (VRMOD) provides a universal coordinate reference system for regulatory sequences across 309 vertebrate genomes and enables genome-wide annotation of non-coding regulatory elements in any vertebrate species using genomic sequence alone.
Tássia Mangetti Gonçalves, Casey L. Stewart, Samantha D. Baxley et al.· NAR Genomics and Bioinformat...· 0 citations
It is suggested that integrating disease-state transcriptomics with genetic prioritization can refine PD risk-gene nomination and uncover regulatory programs that may be missed by GWAS alone.
Isabel Alfradique-Dunham, Jessie Sanford, Meng-Han Liu et al.· bioRxiv· 0 citations
It is shown that a blood-based circular RNA signature can accurately detect Alzheimer’s disease as well as, or better than, current biomarkers and even predict who will develop symptoms before they appear.
Bridget Phillips, C. Cruchaga· Nature Medicine· 1 citation
Whether these proteins, alone or combined with plasma phosphorylated tau 217 (p‐tau217), predict progression from cognitively unimpaired to symptomatic AD is evaluated.
